We are now in the final phase of the development of ChloraSolv.

A clinical program is ongoing. ChloraSolv has been evaluated in an open randomized controlled study where safety and tolerability were assessed as well as a beneficial outcome on wound size reduction and wound closure. The result of the study was published in Clinical Diabetes and Endocrinology 20161.  We have initiated our second trial together with six sites in Sweden.

The product has been submitted for registration in Europe and we look forward to presenting our unique product to the market in 2019 after receiving regulatory approval.

We are using our proprietary buffered hypochlorite technology to create a new and innovative product ChloraSolv to assist clinicians to effectively debride and clean the wounds to support natural wound healing.

ChloraSolv has been designed to meet the following objectives and customer needs:
  • To facilitate removal of necrotic tissue and biofilm preserving healthy, viable tissue during debridement.
  • The de-vitalized, necrotic tissue shall be is easy to remove by using a blunt instrument and may re-place or reduce the need for sharp debridement
  • Easy to use in primary care and in patients’ homes by a health care professional.
  • Only a short application time shall be needed to enable an efficient wound treatment procedure.
  • The Product shall contain sodium hypochlorite that is a broad-spectrum anti-microbiological agent that reduces the microbiological load as shown in vitro (pH Eur 5.1.11).

Our overall goal is to provide a gentle and effective debridement method that result in improved wound care for healthcare professionals reducing the suffering for patients and the overall cost for the society in treating complicated wounds.

1. Bergqvist K, Almhojd U, Herrmann I, Eliasson B. The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial. Clin Diabetes Endocrinol. 2016;2:6.